OBJECTIVES:  To complement the existing studies about effectiveness of antiviral therapy for genotype 1 chronic hepatitis C by using real-world patients. METHODS:  The effectiveness was analyzed using the healthcare database owned by the valencian regional government (Conselleria de Sanitat Universal i Salut Pública) in Spain. This database contains information about 5 million people. The data was filtered in order to obtain patients with antiviral therapy for genotype 1 chronic hepatitis C those had available information about their viral load twelve weeks after completing treatment. The time period considered was from January to August, 2015. RESULTS:  902 patients were identified. 871 (97%) had no detectable HCV viral load twelve weeks after completing treatment. The effectiveness by treatment was: 98.78% for combination ledipasvir-sofosbuvir (246 patients treated); 94.54% for combination ledipasvir-sofosbuvir-ribavirin (183 patients treated); 91.82% for combination sofosbuvir-simeprevir-ribavirin (159 patients treated); 100% for sofosbuvir-simeprevir (114 patients treated); 100.00% for ombitasvir-paritaprevir-ritonavir-dasabuvir (79 patients treated); 100.00% for ombitasvir-paritaprevir-ritonavir-dasabuvir-ribavirin (77 patients treated); 93.10% for sofosbuvir-daclatasvir-ribavirin (29 patients treated); 100% for sofosbuvir-daclatasvir (8 patients treated); 50% for simeprevir-ribavirin (4 patients treated); 50.00% for sofosbuvir-ribavirin (2 patients treated); and 100.00% for ombitasvir-paritaprevir-ritonavir (1 patient treated). Genotype distribution was: 34% of patients with genotype 1a and 66% of patients with genotype 1b infection. Fibrosis (FIB) stage distribution was: 1.55% FIB0; 2.33% FIB1; 17.18% FIB2; 23.28% FIB3 and 55.65% FIB4. CONCLUSIONS: The analysis using real-world patients confirms the high effectiveness of antiviral therapy for genotype 1 chronic hepatitis C. The results indicate that therapies mostly used are ledipasvir-sofosbuvir and ledispasvir-sofosbuvir-ribavirin. Therapies including sofosbuvir-simeprevir, sofosbuvir-daclatasvir, ombitasvir-paritaprevir-ritonavir-dasabuvir, ombitasvir-paritaprevir-ritonavir-dasabuvi-ribavirin and ombitasvir-paritaprevir-ritonavir achieve the 100% of effectiveness. The less effective therapy is the combination simeprevir-ribavirin and the combination sofosbuvir-ribavirin.